Drug Retail

DINGDANG HEALTH

Meituan Health and Dinging Health Launch New Specification of DaWeike

Dingdang Health repurchased 1.72 million shares

Dingdang Health Technology Announces Narrowed Loss for FY2025

DINGDANG HEALTH released FY2025 9 Months Earnings on March 20, 2026 (BJT), with actual revenue of HKD 3.919 B and EPS of HKD -0.0419

DINGDANG HEALTH released FY2025 Q3 earnings on March 20 (BJT), actual revenue HKD 1.4 B, actual EPS HKD 0.0011

DINGDANG HEALTH released FY2025 earnings on March 20 After-Market BJT, actual revenue HKD 5.342 B (forecast HKD 6.701 B), actual EPS HKD -0.0437 (forecast HKD -0.0111)

DINGDANG HEALTH released FY2025 Q4 earnings on March 20 After-Market (BJT), actual revenue HKD 1.424 B, actual EPS HKD 0.0011

DINGDANG HEALTH to Release FY2025 Earnings on March 20 After-Market (BJT), Forecast Revenue HKD 6.4 B, EPS HKD -0.011

Dingdang Health Lists Novartis' Innovative Drug Alvimopan and Completes First Order

DTLK Health Collaborates with Eli Lilly to Launch Tirzepatide in Guangzhou and Shenzhen Pharmacies

DINGDANG HEALTH released FY2025 Q1 earnings on August 22 (BJT), actual revenue HKD 1.246 B, actual EPS HKD -0.0212

DINGDANG HEALTH released FY2025 Semi-Annual earnings on August 22 After-Market BJT, actual revenue HKD 2.519 B, actual EPS HKD -0.043

DINGDANG HEALTH released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue HKD 1.273 B, actual EPS HKD -0.0217

Dingdang Health Semi-Annual Report: Revenue Growth, Narrowed Losses

Dingdang Health FY2025 Semi-Annual Earnings Release on August 22, 2025 (BJT)

Benzanatamab (BGB-A1217) Launches and First Sale at Dingdang Health Pharmacy

Dingdang Health Upgrades Smart Pharmacy System Based on AI

Didang Quick Medicine Launches 15-Minute Emergency Drug Delivery Service

Dingdang Health Non-Executive Director Change

Dingdang Health Technology Group's 2024 Annual Performance Report Shows Revenue Decline and Increased Losses

FAMEGLOW

HAICHANG HLDG

NEW GONOW RV

TJCD

ZHONGSHENJIANYE

HUISHENG INTL

EASYHOLD GROUP

CH CITY INFRA

INTELLIMARK W27

51WORLD

09886

DINGDANG HEALTH is responding to the consumption changes of young customers by launching the "Lazy Health" service to meet immediate and personalized needs. Through "28-minute home delivery" of medications and integration with Huawei's HarmonyOS for voice search purchasing, it enhances user experience. In addition, the AI health assistant "Smart DINGDANG" covers over 80% of medication inquiries, providing a one-stop health management solution and actively responding to the multidimensional needs of young consumers

同壁财经

MEITUAN

MEITUAN-WR

Meituan

Meituan HK SDR 5to1

The young consumer group leads "lazy health," and DINGDANG HEALTH's multi-dimensional layout aligns with consumption changes

510660

159929

516610

512010

513120

589720

DINGDANG HEALTH announced its 2025 annual performance, with revenue recorded at 4.888 billion RMB, an increase of 4.7% year-on-year. The loss narrowed from 376 million RMB in the previous year to 49.02 million RMB, with a loss per share of 0.04 RMB. No final dividend will be distributed

AASTOCKS

ChinaAMC SSE Health Care ETF Initiating Fund

China Universal 800 Health Care ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

"DINGDANG HEALTH" narrowed its annual loss to 49.02 million RMB

DINGDANG HEALTH expects that the annual net loss for the year ending December 31, 2025, will significantly narrow by over 80% compared to approximately RMB 380 million for the fiscal year 2024. The reasons for the improvement include: a significant reduction in goodwill impairment losses accrued in the fiscal year 2024, continuous optimization of urban layout strategies, focusing on core first-tier cities, expanding the smart pharmacy network, and strengthening supply chain service capabilities while optimizing the product sales mix to enhance overall operational efficiency and profitability

Tasty Money

DINGDANG HEALTH (9886) expects its net loss for the last fiscal year to narrow by more than 80% year-on-year

01069

AFJKU

Dingdang Health Technology Group Ltd. has announced its board and committee lineup to enhance governance. Yang Wenlong is appointed as chairman and president, supported by four executive directors, one non-executive director, and three independent non-executive directors. The audit committee will be chaired by independent director Jiang Shan, while Yang leads the nomination committee and Fan Zhenhong heads the remuneration committee. This structure aims to strengthen corporate governance and boost investor confidence. Dingdang Health, listed in Hong Kong, focuses on health technology and services, with a market cap of HK$1.17B.

DINGDANG HEALTH(09886.HK)

The young consumer group leads "lazy health," and DINGDANG HEALTH's multi-dimensional layout aligns with consumption changes

"DINGDANG HEALTH" narrowed its annual loss to 49.02 million RMB

DINGDANG HEALTH (9886) expects its net loss for the last fiscal year to narrow by more than 80% year-on-year

Dingdang Health Defines Board and Committee Lineup to Bolster Governance